Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK and Safety of GV-971 in Healthy Chinese Subjects
NCT03715114Phase 1Unknown
- Sponsor
- Green Valley
- Start
- Oct 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sodium oligomannate in Alzheimer's disease (AD) (4 arms), sponsored by Green Valley. Primary endpoints: Peak Plasma Concentration at 7 day, Half Life Time at 7 day and 2 more. Status: unknown.
02
Drugs
sodium oligomannate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03715114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715114.